To access all features of this site, you must enable Javascript. Here are the instructions for enabling Javascript in your web browser.
To carry out their activities, Research Teams of the Frédéric Joliot Institute for Life Sciences have developed high-profile technological platforms in many areas : biomedical imaging, structural biology, metabolomics, High-Throughput screening, level 3 microbiological safety laboratory...
Within the Institute, the "Funding Research and Technology Transfer" team is at your disposal to identify the scientists and the skills you need to set up a joint project, to define the terms of a collaboration contract or study. Whether you are an academic, a SME or an industrialist, our team informs and advices you about the possibilities of consortium assembly, technology transfer, patent licensing or use of our platforms. The team is also at the disposal of the researchers of the institute to accompany them in achieving their valorization objectives.
All the news of the Institute of life sciences Frédéric Joliot
Research Teams from the Curie Institute, the Gustave Roussy Institute, as well as the biophysics teams from the Institute of Chemistry of Natural Substances and SB2SM (I2BC@Saclay) met to systematically identify structural defects and BRCA1 proteins encoded by variants of the BRCA1 gene, a gene predisposing to breast and ovarian cancer. Their results make it possible to propose a classification of these variants (neutral versus causal).
A SB2SM Research Team (I2BC@Saclay) solved by crystallography the structure of a ternary protein complex at the interface between the nuclear envelope (emerin and lamin A / C) and the genome (BAF). In collaboration with Teams from Paris-Sud and Paris-Diderot Universities, the structure analysis, as well as in vitro interaction and proximity experiments in cellulo, suggests that a lack of interaction between the lamina A / C (nucleoskeleton) and chromatin-associated protein (BAF) may be one of the mechanisms responsible for premature aging syndromes.
SHFJ Researchers (IMIV), in collaboration with Vienna University, studied the brain transport of a drug, called metoclopramide. Radiolabelling of carbon-11 metoclopramide and PET imaging showed that a transporter of the blood-brain barrier, P-glycoprotein, blocked not only the entry of the drug into the brain but also facilitated the elimination to the blood. This result demonstrates for the first time in vivo and non-invasively a detoxification system able to eliminate certain compounds of the brain.
In studies published in ChemPhotoChem, I2BC@Saclay, SCBM and ICMMO researchers have developed a gentle method for photo-CO2 reduction by molecular catalysts, followed by a carbonylation reaction that immediately reuse the CO produced. This device can be used for the introduction of radioactive carbon atoms into molecules of therapeutic interest.
Directed by Thierry Meinnel, it carries out research on Integrative Biology of the Cell.
Directed by Christophe Junot, it carries out research on Molecular Innovation for human health.
Directed by Stanislas Dehaene, it is a Research Infrastructure designed to study the singularity of the brain.
Directed by Vincent Lebon, it carries out research in Molecular and Functional Imaging and provides a medical service mission.
Conference | CEA Paris-Saclay, site de Fontenay-aux-Roses, IDMIT, Bâtiment 62, Salle Dormont
Grasse
The 4th European Workshop of sub-units NF-kB will be held from 8 - 10 October 2018 in Grasse.
Event | Fontenay aux Roses
The 12th International Conference on Health Effects after Radionuclide Incorporation is organized from 8 to 11 October 2018 in Fontenay-Aux-Roses.
CEA is a French government-funded technological research organisation in four main areas: low-carbon energies, defense and security, information technologies and health technologies. A prominent player in the European Research Area, it is involved in setting up collaborative projects with many partners around the world.